Saroglitazar is under clinical development by Zydus Therapeutics and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase II drugs for ...

One 97 Communications Paytm, Zomato, APL Apollo Tubes, Central Bank of India, Dixon Technologies, IDBI Bank, Indian Overseas Bank, Indian Railway Finance Corporation, ICICI Securities, Jammu & Kashmir ...

One 97 Communications Paytm, Zomato, APL Apollo Tubes, Central Bank of India, Dixon Technologies, IDBI Bank, Indian Overseas Bank, Indian Railway Finance Corporation, ICICI Securities, Jammu ...

Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to manufacture its generic version of Paliperidone extended-release tablets, used to treat ...

Biden was the seventh president to continue the modern tradition of leaving a letter to his successor. Biden was the sixth president to leave a letter to a successor of another political party and the ...

Indian markets closed on a positive note on Monday with the 30-share Sensex gaining 454 points or 0.59 per cent to settle at ...

The trend is also visible in other FMCG companies. Zydus Wellness, the company behind brands like Complan and Glucon-D, is expanding its rural coverage, focusing on increasing penetration where brands ...

The often-dreaded cover letter is your secret weapon for standing out. Despite its importance, only 38% of candidates submit one for a job posting when required. The truth? A generic, formulaic ...

In his letter BRT not the answer (Jan. 14), Walt Lonc claims bridges linking Colonel Talbot to Hyde Park Road and Gainsborough Road to Windermere Road would be better than completing a north end BRT.

A collection of letters sent between Winnie the Pooh author AA Milne, illustrator E.H. Shepherd and publisher Frederick Muller is to be sold at auction. They were discovered among papers belonging ...

The initial burst of new launches by Sun, Cipla, Zydus and Lupin are in the mid-to-late stage of product lifecycle. However, the industry as a whole has been downplaying the threat from trade ...

Nomura has upgraded Zydus Lifesciences Ltd. to a 'buy' from its earlier 'neutral' stance, raising the target price to Rs 1,140 from Rs 1,030, implying a potential upside of 16%. Robust earnings growth ...